Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 12/20 | 0.50 |
| ▸ | PARP11 | Q9NR21 | 9/20 | 0.50 |
| ▸ | PARP1 | P09874 | 10/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | RAF1 | P04049 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.35 |
| ▸ | F7 | P08709 | 1/20 | 0.33 |
| ▸ | F3 | P13726 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22982078 | 1.00 | PARP10 (0.50) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL29698311 | 0.83 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL22990374 | 0.83 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL22981764 | 0.83 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL29698267 | 0.83 | PARP10 (0.51) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL23952300 | 0.74 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL23951998 | 0.74 | PARP10 (0.56) | PARP10PARP11PARP1ACHERAF1 | |
| SCHEMBL22982047 | 0.74 | PARP10 (0.56) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL22990298 | 0.74 | PARP10 (0.56) | PARP10PARP11PARP1PDPK1ACHE | |
| SCHEMBL24886285 | 0.74 | PARP10 (0.56) | PARP10PARP11PARP1PDPK1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115109072-A | GPR84 antagonist and preparation method and application thereof | 武汉人福创新药物研发中心有限公司 | 2022-09-27 | — | — | CN | disclosed |
| WO-2022194267-A1 | GPR84 ANTAGONIST, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 武汉人福创新药物研发中心有限公司 | 2022-09-22 | — | — | WO | disclosed |
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | NOVARTIS AG (CH) | 2022-09-15 | — | — | US | disclosed |
| EP-4010334-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | Novartis AG (CH) | 2022-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220289732-A1 | HETEROCYCLIC WDR5 INHIBITORS AS ANTI-CANCER COMPOUNDS | WDR5, WDR77, WDR1 | PARP10 512/4885PARP11 326/4885PARP1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.